SOURCE: BioCentury

September 06, 2007 08:15 ET

Newsmaking Biotechs Gain 14% in Market Cap This Year

Today's 14th Annual NewsMakers in the Biotech Industry Investor Conference Presents 36 Companies With Value-Shaping Milestones for Investors to Watch

NEW YORK, NY--(Marketwire - September 6, 2007) - BioCentury Publications, Inc. announced that the robust lineup of companies presenting today at the 14th Annual NewsMakers in the Biotech Industry conference has added $10.2 billion in market capitalization so far in 2007 and has a host of upcoming milestones to carry Wall Street into 2008.

Collectively, the market value of the 36 Presenting Companies in the NewsMakers Class of 2007 stood at $82.4 billion at the beginning of September, up 14.1 percent since January, easily surpassing the market cap weighted NASDAQ Composite Index (up 7.5 percent). Future growth is being fueled by $1.8 billion in fresh capital raised to date in 2007, on top of $4.8 billion raised in 2006.

Future value is determined by future performance, which is why NewsMakers helps investors focus on key upcoming events. Collectively, the Class of 2007 is preparing to file 14 New Drug Applications (NDAs) and/or Biologics License Applications (BLAs) within the next year. More news will be coming from pipelines that include 41 ongoing Phase III clinical trials and 70 Phase II studies. These companies -- which are focused on pain, obesity, cancer, infectious diseases, autoimmune and cardiopulmonary disorders -- already market a combined 37 products and have four compounds under review by the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA).

This pioneering conference, organized by BioCentury and Thomson Financial, has earned Wall Street's respect for its independently selected investment stories and open door to the Wall Street community. That's why NewsMakers has enjoyed enduring sponsorship from leading financial institutions and industry service firms, all of which recognize the value of a turf-neutral venue for the corporate and investment communities to do business.

"Premier biotech portfolio managers and analysts congregate at NewsMakers because they know they will see independently selected and investor-validated stories with potentially transformational milestones in key disease areas," said BioCentury Publisher Eric Pierce. "Once again, more than 800 biotech investors, analysts, company management teams and business development executives have registered to attend. They understand NewsMakers is an efficient, one-day, one-stop opportunity to jump-start the fall investment season."

"We are proud of our long-term partnership with NewsMakers," said Laura Berezin, Partner at Cooley Godward Kronish LLP, this year's Gold Sponsor. "The meeting provides Cooley with superb visibility among the top decision makers on Wall Street and within the biopharma industry. It delivers tremendous value to the institutional investment community year after year."

The 2007 Sponsors

BioCentury and Thomson Financial are pleased to acknowledge the leadership provided by the NewsMakers Sponsors, whose continuing support validates the turf-neutral approach. In addition to Gold Sponsor Cooley Godward Kronish, this impressive group includes the Acumen BioFin Division of Rodman & Renshaw, CIBC World Markets, GE Healthcare Financial Services - Life Science Finance, JMP Securities, Kingsbridge Capital, Leerink Swann, NYSE Euronext, Pacific Growth Equities, RBC Capital Markets and SIG Susquehanna Financial Group.

NewsMakers Class of 2007

The complete list of 36 Presenting Companies and their upcoming milestones can be found at www.biocentury.com/NewsMakers2007. Webcasts of company presentations can be found through direct links on individual company websites.

About BioCentury

BioCentury Publications, Inc., based in San Carlos, Calif., provides essential industry intelligence from five offices in the U.S. and Europe to a global audience of biotech and pharmaceutical executives and investors. With 15 years of service, the company is privately owned and does not invest in or recommend individual stock purchases. Subscribers therefore benefit from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, collaborative industry conferences and online databases. BioCentury's newest Data Solutions offering for Premium Subscribers -- BCIQ: BioCentury Online Intelligence -- is one more reason why BioCentury is BioPharma's Knowledge Center™. For more information, visit www.biocentury.com or contact BioCentury directly via email at www.biocentury.com/SubscriberServices.

About Thomson Financial

Thomson Financial, with 2006 revenues of US$2 billion, is a provider of information and technology solutions to the worldwide financial community. Through the widest range of products and services in the industry, Thomson Financial helps clients in more than 70 countries make better decisions, be more productive and achieve superior results. Thomson Financial is part of The Thomson Corporation (www.thomson.com), a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC) (TSX: TOC). For more information about Thomson Financial, visit www.thomson.com/solutions/financial.

BioCentury®; The Bernstein Report on BioBusiness®; The BioCentury 100™; The Clear Route to ROI™, Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™ are trademarks of BIOCENTURY PUBLICATIONS, INC. Copyright © 2007. ALL RIGHTS RESERVED.

Contact Information

  • Media Inquiries Contact:
    Lana Guernsey
    WeissComm Partners
    1-415-946-1073 office
    1-650-504-5454 mobile
    Email Contact